Renal microvascular dysfunction, hypertension and CKD progression

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 1, 2013, Pages 1-9

  Bidani, Anil K ^a   Polichnowski, Aaron J ^a   Loutzenhiser, Rodger ^b   Griffin, Karen A ^a  

^a HINES VA HOSPITAL   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

angiotensin II; autoregulation; chronic kidney disease; hypertension; nitric oxide

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; HYDRALAZINE; NITRIC OXIDE; VOLTAGE GATED CALCIUM CHANNEL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BAROTRAUMA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; GLOMERULOSCLEROSIS; HUMAN; KIDNEY BLOOD FLOW; PRIORITY JOURNAL; RENAL PROTECTION; RENOVASCULAR DISEASE; RENOVASCULAR HYPERTENSION; REVIEW; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANGIOTENSIN II; BLOOD PRESSURE; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; HYPERTENSION, RENAL; KIDNEY GLOMERULUS; MICROVESSELS; NITRIC OXIDE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84871733181     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835b36c1     Document Type: Review

References (87)

1. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49:1774-F1777.
2. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85-93.
3. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008; 294:F685-F696.
4. Bidani AK, Mitchell KD, Schwartz MM, et al. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int 1990; 38:28-38.
5. Griffin KA, Picken MM, Churchill M, et al. Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 2000; 11:497-506.
6. Arendshorst WJ, Gottschalk CW. Glomerular ultrafiltration dynamics: euvolemic and plasma volume-expanded rats. Am J Physiol 1980; 239: F171-F186.
7. Tucker BJ, Blantz RC. Effects of glomerular filtration dynamics on the glomerular permeability coefficient. Am J Physiol 1981; 240:F245-F254.
8. Bidani AK, Griffin KA, Williamson G, et al. Protective importance of the myogenic response in the renal circulation. Hypertension 2009; 54:393-398.
9. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6:643-656.
10. Harris RC, Neilson EG. Toward a unified theory of renal progression. Annu Rev Med 2006; 57:365-380.
11. Kagami S. Involvement of glomerular renin-angiotensin system (RAS) activation in the development and progression of glomerular injury. Clin Exp Nephrol 2012; 16:214-220.
12. Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 2010; 6:667-678.
13. Ruster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011; 22:1189-1199.
14. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21:1819-1834.
15. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5 Suppl 1):S1-290.
16. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003; 289:2560-2572.
17. Olson JL. Renal disease caused by hypertension. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 937-990.
18. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.
19. Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008; 168:832-839.
20. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-845.
21. Hill GS. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 2008; 17:266-270.
22. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175-1184.
23. Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int 2002; 62:172-180.
24. Bohle A, Ratschek M. The compensated and the decompensated form of benign nephrosclerosis. Pathol Res Pract 1982; 174:357-367.
25. Cupples WA, Braam B. Assessment of renal autoregulation. Am J Physiol Renal Physiol 2007; 292:F1105-F1123.
26. Just A. Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol Regul Integr Comp Physiol 2007; 292:R1-17.
27. Loutzenhiser R, Griffin K, Williamson G, Bidani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006; 290:R1153-R1167.
28. Thomson SC, Blantz RC. Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis. J Am Soc Nephrol 2008; 19:2272-2275.
29. Chen J, Sgouralis I, Moore LC, et al. A mathematical model of the myogenic response to systolic pressure in the afferent arteriole. Am J Physiol Renal Physiol 2011; 300:F669-F681.
30. Williamson GA, Loutzenhiser R, Wang X, et al. Systolic and mean blood pressures and afferent arteriolar myogenic response dynamics: a modeling approach. Am J Physiol Regul Integr Comp Physiol 2008; 295:R1502-R1511.
31. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999; 79:387-423.
32. Chilton L, Smirnov SV, Loutzenhiser K, et al. Segment-specific differences in the inward rectifier K(\+) current along the renal interlobular artery. Cardiovasc Res 2011; 92:169-177.
33. Drummond HA, Grifoni SC, Abu-Zaid A, et al. Renal inflammation and elevated blood pressure in a mouse model of reduced {beta}-ENaC. Am J Physiol Renal Physiol 2011; 301:F443-F449.
34. Grifoni SC, Chiposi R, McKey SE, et al. Altered whole kidney blood flow autoregulation in a mouse model of reduced beta-ENaC. Am J Physiol Renal Physiol 2010; 298:F285-F292.
35. Kirton CA, Loutzenhiser R. Alterations in basal protein kinase C activity modulate renal afferent arteriolar myogenic reactivity. Am J Physiol 1998; 275 (2 Pt 2):H467-H475.
36. Roman RJ, Harder DR. Cellular and ionic signal transduction mechanisms for the mechanical activation of renal arterial vascular smooth muscle. J Am Soc Nephrol 1993; 4:986-996.
37. Sharif-Naeini R, Dedman A, Folgering JH, et al. TRP channels and mechanosensory transduction: insights into the arterial myogenic response. Pflugers Arch 2008; 456:529-540.
38. Sorensen CM, Giese I, Braunstein TH, et al. Role of Connexin40 in the autoregulatory response of the afferent arteriole. Am J Physiol Renal Physiol 2012; 303:F855-F863.
39. Lai EY, Solis G, Luo Z, et al. p47(phox) is required for afferent arteriolar contractile responses to angiotensin II and perfusion pressure in mice. Hypertension 2012; 59:415-420.
40. Lai EY, Wellstein A, Welch WJ, Wilcox CS. Superoxide modulates myogenic contractions of mouse afferent arterioles. Hypertension 2011; 58:650-656.
41. Saeed A, Dibona GF, Marcussen N, Guron G. High-NaCl intake impairs dynamic autoregulation of renal blood flow in ANG II-infused rats. Am J Physiol Regul Integr Comp Physiol 2010; 299:R1142-R1149.
42. Sharma K, Cook A, Smith M, et al. TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 2005; 288:F1069-F1077.
43. Vavrinec P, van Dokkum RP, Goris M, et al. Losartan protects mesenteric arteries from ROS-associated decrease in myogenic constriction following 5/6 nephrectomy. J Renin Angiotensin Aldosterone Syst 2011; 12:184-194.
44. Bidani AK, Griffin KA, Epstein M. Hypertension and chronic kidney disease progression: why the suboptimal outcomes? Am J Med 2012; 125:1057-1062.
45. Griffin KA, Picken MM, Bidani AK. Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in the rat. Kidney Int 2004; 65:209-218.
46. Kurtz TW, Griffin KA, Bidani AK, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 2: blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 2005; 45:299-310.
47. Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009; 53:20-27.
48. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96:793-800.
49. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006; 1:1054-1065.
50. Bidani AK, Griffin KA. The benefits of renin-angiotensin blockade in hypertension are dependent on blood-pressure lowering. Nat Clin Pract Nephrol 2006; 2:542-543.
51. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57:1651-1661.
52. Griffin KA, Picken M, Bidani AK. Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 1994; 46:1010-1018.
53. Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 2003; 41:193-196.
54. Leelahavanichkul A, Yan Q, Hu X, et al. Angiotensin II overcomes straindependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int 2010; 78:1136-1153.
55. Deng A, Arndt MA, Satriano J, et al. Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade. Am J Physiol Renal Physiol 2010; 299:F1365-F1373.
56. Singh P, Deng A, Blantz RC, Thomson SC. Unexpected effect of angiotensin AT1 receptor blockade on tubuloglomerular feedback in early subtotal nephrectomy. Am J Physiol Renal Physiol 2009; 296:F1158-F1165.
57. Inscho EW, Lewis K. Dahl Memorial Lecture. Mysteries of renal autoregulation. Hypertension 2009; 53:299-306.
58. Inscho EW, Cook AK, Clarke A, et al. P2X1 receptor-mediated vasoconstriction of afferent arterioles in angiotensin II-infused hypertensive rats fed a highsalt diet. Hypertension 2011; 57:780-787.
59. Inscho EW, Cook AK, Murzynowski JB, Imig JD. Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. J Hypertens 2004; 22:811-818.
60. Inscho EW, Imig JD, Deichmann PC, Cook AK. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. J Am Soc Nephrol 1999; 10 (Suppl 11):S178-S183.
61. Guan Z, Fuller BS, Yamamoto T, et al. Pentosan polysulfate treatment preserves renal autoregulation in ANG II-infused hypertensive rats via normalization of P2X1 receptor activation. Am J Physiol Renal Physiol 2010; 298:F1276-F1284.
62. Sasser JM, Moningka NC, Cunningham MW Jr, et al. Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2010; 298:R740-R746.
63. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004; 44:595-601.
64. Brands MW, Banes-Berceli AK, Inscho EW, et al. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 2010; 56:879-884.
65. Guan Z, Willgoss DA, Matthias A, et al. Facilitation of renal autoregulation by angiotensin II is mediated through modulation of nitric oxide. Acta Physiol Scand 2003; 179:189-201.
66. Just A, Ehmke H, Wittmann U, Kirchheim HR. Role of angiotensin II in dynamic renal blood flow autoregulation of the conscious dog. J Physiol 2002; 538 (Pt 1):167-177.
67. Bidani AK, Abu-Naser M, Abu-Amarah I, et al. Pressure-flow relationships and transfer functions in kidneys of angiotensin II infused conscious rats. J Am Soc Nephrol 2004; 15:208A.
68. Boulos N, Helle F, Dussaule JC, et al. Notch3 is essential for regulation of the renal vascular tone. Hypertension 2011; 57:1176-1182.
69. Baylis C. Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Nephrol Hypertens 2012; 21:1-6.
70. Baylis C, Qiu C. Importance of nitric oxide in the control of renal hemodynamics. Kidney Int 1996; 49:1727-1731.
71. Griffin K, Polichnowski A, Licea-Vargas H, et al. Large BP-dependent and-independent differences in susceptibility to nephropathy after nitric oxide inhibition in Sprague-Dawley rats from two major suppliers. Am J Physiol Renal Physiol 2012; 302:F173-F182.
72. Dautzenberg M, Keilhoff G, Just A. Modulation of the myogenic response in renal blood flow autoregulation by NO depends on endothelial nitric oxide synthase (eNOS), but not neuronal or inducible NOS. J Physiol 2011; 589 (Pt 19):4731-4744.
73. Wang X, Cupples WA. Interaction between nitric oxide and renal myogenic autoregulation in normotensive and hypertensive rats. Can J Physiol Pharmacol 2001; 79:238-245.
74. Erdely A, Wagner L, Muller V, et al. Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 2003; 14:2526-2533.
75. Fujihara CK, De Nucci G, Zatz R. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 1995; 5:1498-1507.
76. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161:239-248.
77. Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutiveNO synthases in mammalian kidney. Am J Physiol 1995; 268 (5 Pt 2):F885-F898.
78. Elger M, Sakai T, Kriz W. The vascular pole of the renal glomerulus of rat. Adv Anat Embryol Cell Biol 1998; 139:1-98.
79. Griffin KA, Bidani AK. Angiotensin II type 2 receptor in chronic kidney disease: the good side of angiotensin II? Kidney Int 2009; 75:1006-1008.
80. Bidani AK, Picken M, Hacioglu R, et al. Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance. Am J Physiol Renal Physiol 2007; 292:F647-F654.
81. Brosius FC 3rd, Alpers CE, Bottinger EP, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20:2503-2512.
82. Kriz W, Elger M, Mundel P, Lemley KV. Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 1995; 5:1731-1739.
83. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83:253-307.
84. Fukuda A, Wickman LT, Venkatareddy MP, et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 2012; 81:40-55.
85. Sachs N, Claessen N, Aten J, et al. Blood pressure influences end-stage renal disease of Cd151 knockout mice. J Clin Invest 2012; 122:348-358.
86. Song YR, You SJ, Lee YM, et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 2010; 25:77-85.
87. Tanaka T, Kojima I, Ohse T, et al. Cobalt promotes angiogenesis via hypoxiainducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 2005; 85:1292-1307.